Abeona Therapeutics (ABEO) Common Equity (2016 - 2025)
Historic Common Equity for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $171.2 million.
- Abeona Therapeutics' Common Equity rose 27409.17% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 27409.17%. This contributed to the annual value of $44.0 million for FY2024, which is 19698.5% up from last year.
- Abeona Therapeutics' Common Equity amounted to $171.2 million in Q3 2025, which was up 27409.17% from $163.6 million recorded in Q2 2025.
- Abeona Therapeutics' Common Equity's 5-year high stood at $171.2 million during Q3 2025, with a 5-year trough of -$8.9 million in Q1 2024.
- In the last 5 years, Abeona Therapeutics' Common Equity had a median value of $41.4 million in 2025 and averaged $51.1 million.
- Over the last 5 years, Abeona Therapeutics' Common Equity had its largest YoY gain of 68374.53% in 2024, and its largest YoY loss of 14739.06% in 2024.
- Quarter analysis of 5 years shows Abeona Therapeutics' Common Equity stood at $42.4 million in 2021, then plummeted by 36.84% to $26.8 million in 2022, then crashed by 44.6% to $14.8 million in 2023, then skyrocketed by 196.99% to $44.0 million in 2024, then surged by 288.89% to $171.2 million in 2025.
- Its Common Equity was $171.2 million in Q3 2025, compared to $163.6 million in Q2 2025 and $41.4 million in Q1 2025.